Collaborations Between Biotech And Pharmaceutical Companies: Dec. 23, 2005-Feb. 22, 2006
Biotech Co.* | Pharma Co. | Type/Product Area | Terms/Details (Date) |
Ablynx NV* | Kirin Brewery Co. Ltd. (Japan) | Collaboration focused on the use of Nanobodies as therapeutic products | Specifics on the research and license agreement were not disclosed (2/9) |
Ablynx NV* | Novartis AG (Switzerland) | Deal to to discover and develop Nanobody-based drugs against a number of targets in a range of diseases | Ablynx gets up-front fees, license fees and R&D funding and is eligible to receive milestone and royalty payments (1/18) |
Ablynx NV* | Centocor Inc. (unit of Johnson & Johnson) | Deal to jointly work on approaches for administration and delivery of Nanobody-based therapeutics | Centocor will fund the research; further terms were not disclosed (1/11) |
ActiveSight | Novo Nordisk A/S (Denmark) | ActiveSight will provide protein crystallography services for Novo | ActiveSight will co-crystallize Novo molecules with proteins expressed by ActiveSight; terms were not disclosed (1/23) |
Affymax Inc.* | Takeda Pharmaceutical Co. Ltd. (Japan) | Takeda got rights to develop and sell Affymax's anemia product Hematide in Japan | Affymax gets a $17M up-front payment and a $10M equity investment; it also could get clinical and regulatory milestones of $75M, and double-digit royalties on sales (2/13) |
Alkermes Inc. | Eli Lilly and Co. | Deal to develop inhaled formulations of parathyroid hormone using Alkermes' AIR pulmonary delivery system | Alkermes gets up-front, development and potential milestone payments, as well as royalties on any sales; Lilly's PTH product Forteo was approved in 2002 (1/9) |
Alnylam | Novartis AG (Switzerland) | They formed a collaboration to develop RNAi therapeutics for pandemic flu | The deal is in addition to a broad collaboration they signed in September 2005; terms were not disclosed (2/21) |
Alnylam | Dharmacon Inc. (unit of Fisher Biosciences) | Dharmacon got nonexclusive rights to provide RNAi research products and services under Kreutzer-Limmer patents | The patent family covers small interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the deal were not disclosed (1/5) |
AlphaVax Inc.* | Wyeth | New deal gives Wyeth exclusive access to all relevant AlphaVax technologies for certain infectious diseases | The enhancement of their 1998 deal refocuses the disease targets and adds exclusivity; AlphaVax gets an equity investment and is entitled to significantly more funding than in the original deal (1/12) |
Amira | F. Hoffmann- La Roche Ltd. (Switzerland) | Amira will optimize compounds against inflammatory disease targets; separately, Amira got an option to license two clinical-stage Roche compounds | Under the research deal, Roche would have opt-in rights on two programs, for which it could pay Amira up to $287M, plus royal- ties; in the license deal, Amira has a one- year option to the Roche programs in certain indications; Roche could get significant Almira equity, $20M in milestones and royalties on sales (1/9) |
Aphton Corp. | BioWa Inc. (unit of Kyowa Hakko Kogyo Co. Ltd.; Japan) | Apthon subsidiary Igeneon got nonexclusive rights to use BioWa's Potelligent technology | Igeneon will use the technology in development of a next-generation Lewis Y-specific antibody, IGN312; terms of the deal were not disclosed (2/14) |
Argenta | Dr. Reddy's Laboratories (India) | Deal to jointly develop clinical candidates from a class of Dr. Reddy compounds for treating chronic obstructive pulmonary disease | They will fund development through Phase IIa trials, then continue development or license out candidates; terms of the deal were not disclosed (2/2) |
Asterand plc | BTG plc (UK) | BTG got rights to a series of preclinical compounds for treating pain and related conditions | Asterand gets an undisclosed up-front payment and could earn milestone and royalty payments in the deal (1/30) |
Astex | Pfizer Inc. | Pfizer got nonexclusive rights to use Cytochrome P450 crystal structure data | Astex gets an up-front fee in the deal; further terms were not disclosed (1/24) |
Athersys Inc.* | Bristol-Myers Squibb Co. | They extended deal under which Athersys is applying its RAGE technology to provide drug targets to BMS | Athersys is entitled to license fees for targets delivered to BMS, as well as potential milestone and royalty payments on resulting compounds (1/6) |
AVEO | Mitsubishi Pharma Corp. (Japan) | AVEO acquired rights outside Asia to Mitsubishi's kinase inhibitor MP-412 | AVEO intends to start clinical studies by mid-2006; the initial focus is solid tumors; terms of the deal were not disclosed (1/5) |
Avigen Inc. | SDI Diagnostics International Ltd. (unit of Sanochemia Pharmazeutika AG; Austria) | Avigen got North American rights to formulations of tolperisone (AV650), a small molecule for treating neuromuscular conditions | SDI gets $3M up front and is eligible to receive milestone and royalty payments; the product is approved in Europe; SDI also will manufacture the product (1/16) |
Axonyx Inc. | Daewoong Pharmaceutical Co. Ltd. (South Korea) | Daewoong got rights to sell the Alzheimer's drug candidate Phenserine in South Korean | Axonyx is entitled to royalty payments; Daewoong is responsible for development in South Korea; further terms were not disclosed (1/4) |
BioCryst | Mundipharma International Holdings Ltd. (UK) | Mundipharma got rights to Fodosine in oncology fields, in Europe, Asia and Australia | BioCryst gets $10M up front and up to $155M in milestone payments, as well as royalties on sales; Mundipharma also will pay up to $25M in development costs (2/2) |
BioSphings | Shogoo Pharmaceuticals KK (Japan) | Shogoo got worldwide rights to BioSphings' SPK-0601, a small molecule that acts on viral gene expression | BioSphings gets an up-front payment as well as potential milestone and royalty payments (2/2) |
Biovitrum AB* | Helsinn Healthcare SA (Switzerland) | Biovitrum got exclusive rights to the antiemetic drug Aloxi in the Nordic region | The product already is on the market in parts of Europe; terms of the deal were not disclosed (2/16) |
Cadence | Bristol-Myers Squibb Co. | Cadence acquired rights in the U.S. and Canada to an intravenous formulation of acetaminophen | BMS gets an up-front payment and could receive milestone and royalty payments in the deal (2/22) |
Caprion | Berlex Inc. (unit of Schering AG; Germany) | Collaboration using Caprion's CellCarta proteomics platform for biomarker discovery | Caprion will identify biomarkers in plasma resulting from administration of preclinical Berlex compounds; terms were not disclosed (1/24) |
Cara | ALZA Corp. (unit of Johnson & Johnson) | ALZA got rights to Cara's peripherally acting pain drug candidate CR665, which has completed a Phase Ia trial | Cara gets an up-front payment and could receive milestone payments and royalties on sales; it also retained a U.S. co-promotion option on intravenous products (1/5) |
Celera | Applied Biosystems Group | Celera acquired ABG's 50% interest in their Celera Diagnostics joint venture | Both Celera and ABG are units of Applera Corp.; terms of the restructuring were not disclosed (1/9) |
Cell Signaling | AstraZeneca plc (UK) | CST's PhosphoScan technology will be used on research on kinase-targeted compounds | The technology enables discovery of drug target phospho-profiles in cells and disease tissue; terms were not disclosed (1/10) |
Cephalon Inc. | Mylan Laboratories Inc. | Deal to use Mylan's transdermal technology to develop products for pain and central nervous system disorders | Mylan is entitled to milestone and royalty payments in the deal; further terms were not disclosed (1/11) |
Cerimon | Novartis Pharma AG (Switzerland) | Cerimon acquired worldwide rights to Simulect (basiliximab) for treating inflammatory bowel disease | Novartis already markets the antibody for preventing organ rejection in renal transplant recipients; Cerimon is eligible for milestone payments in the deal, and Novartis would get a share of revenues on sales for IBD (2/21) |
ChemGenex | Merck KGaA (Germany) | ChemGenex will provide preclinical support in the areas of diabetes, insulin resistance and complications | Payments under the three-year deal will depend on the amount and type of support provided; the deal followed target discovery work between the companies (1/16) |
Chromos | Pfizer Inc. | Expanded deal under which Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein | They also will collaborate to genetically engineer production cell lines; Pfizer will fund the new programs (1/9) |
Ciphergen | Sanofi-Aventis Group(France) | Deal to discover biomarkers for a preclinical study in the field of oncology | Ciphergen will use its proteomics technologies in the effort; terms of the deal were not disclosed (2/7) |
Codexis Inc.* | Bristol-Myers Squibb Co. | They extended deal focused on improving the biocatalyst productivity of a BMS product | Codexis gets additional research funding under the extension of the May 2005 deal; terms were not disclosed (1/31) |
Cue Biotech | H. Lundbeck A/S (Denmark) | Deal to discover and develop drugs for central nervous system diseases and disorders | The focus is on small molecules targeting G protein- coupled receptors; terms of the deal were not disclosed (1/24) |
CytoGenix | Fast Trak BioDefense (unit of GE Healthcare) | Collaboration to obtain biodefense-related federal contracts | Contract calls for them to compete for federal research projects; terms were not disclosed (12/27) |
Diversa Corp. | BASF (Germany) | Broad agreement to develop products for industrial applications | The deal expands a relationship between them from 2001 for developing biocatalysts; terms were not disclosed (2/16) |
Emisphere | Novartis AG (Switzerland) | A court said Emisphere's deal with Lilly on oral parathyroid hormone was properly terminated as of August 2004 | The ruling allows Emisphere to now license its eligen technology for use with PTH to Novartis for treatment of osteoporosis; Emisphere is entitled to milestone and royalty payments (1/9) |
Endocyte Inc.* | Bristol-Myers | BMS got rights to Endocyte's vitamin-targeting technology for targeting epothilone cancer chemotherapeutic agents | The deal follows an ongoing collaboration; Endocyte gets a $3M license payment and potential milestone and royalty payments (1/5) |
EntreMed | Elan Corp. plc (Ireland) | EntreMed got rights to use Elan's NanoCrystal technology to develop the cancer product candidate Panzem NCD | Elan is eligible to receive milestone and royalty payments in the deal; also, Elan will manufacture Panzem NCD, a NanoCrystal technology formulation of the drug (1/10) |
Epitome | Bristol-Myers Squibb Co. | Epitome will develop biomarker assay panels for BMS | Epitome will use its EpiTag protein measurement platform in the deal; it is entitled to development funding and license fees (1/4) |
EPIX | Schering AG (Germany) | Schering exercised its option to develop a gadofluorine derivative discovered in their collaboration | The product is intended for the diagnosis of atherosclerosis and other vascular diseases; EPIX would get royalties on any resulting sales (2/10) |
Evotec AG | Cellomics Inc. (unit of Fisher Biosciences) | Evotec Technologies GmbH got rights to Cellomics' High Content Screening technology | The companies also are collaborating to develop and market combined offerings in cell biology solutions; terms were not disclosed (1/30) |
Evotec AG | Boehringer Ingelheim started in September 2004 | They expanded and extended drug discovery collaboration research support, along with potential | The focus was extended from GPCR targets to other classes; Evotec gets ongoing FSE:EVT) milestone and royalty payments (1/17) |
Evotec AG | F. Hoffmann- La Roche Ltd. (Switzerland) | Evotec got rights to two monoamine oxidase-B inhibitors that are in Phase I trials for Alzheimer's disease | Roche gets an up-front fee and potential milestone and royalty payments; it also retained a late-stage co- development option; Roche would get Evotec stock upon initiation of Phase II trials (1/9) |
Galapagos NV | BASF (Germany) | They extended three research collaborations into 2006; Galapagos division BioFocus is providing the services | BASF will pay compound supply and access fees in the contract extensions, which are valued at more than €700,000 (2/2) |
Galapagos NV | Boehringer Ingelheim GmbH (Germany) | Three-year deal in field of autoimmune discovery research; Galapagos division BioFocus will do the work | Galapagos gets up-front fees, R&D funding and could receive milestone fees, which together could exceed €2M (1/16) |
GeneGo Inc.* | Merck & Co. Inc. | Merck extended for two years its right to use GeneGo technologies | Merck is using the MetaCore and MetaBase technologies in R&D programs; terms of the deal were not disclosed (1/9) |
G2 Therapies | Novo Nordisk A/S (Denmark) | Deal to develop and market anti-inflammatory drugs based on G2's C5a receptor antibodies | G2 gets $6M up front and up to $96M in milestone payments, as well as royalties on resulting sales; it also gets expense reimbursement (2/8) |
Hybrigenics | Theramex (affiliate of Merck KGaA; Germany) | Hybrigenics got worldwide rights to inecalcitol, a synthetic vitamin D analogue | Hybrigenics intends to develop products for cancer and partner the drug in other indications; terms of the deal were not disclosed (2/7) |
IDM Pharma | Genesis Pharma (Greece) | Genesis got rights in southeast Europe to the immune system stimulator Junovan | The product has completed a Phase III trial in osteosarcoma; IDM is entitled to an upfront license fee and sales-based milestone payments (2/21) |
ImQuest | Samjin Pharmaceutical Co. Ltd. (South Korea) | Deal under which ImQuest will provide preclinical and clinical development support | ImQuest will work on small molecules provided by Samjin; terms of the deal were not disclosed (1/24) |
Innovive | Nippon Shinyaku Co. Ltd. (Japan) | Innovive got all rights outside Japan to NS-187, an inhibitor of Bcr-Abl and Lyn kinase | Innovive will develop the product for chronic myelogenous leukemia; Phase I trials are expected in 2006; terms of the deal were not disclosed (1/5) |
Inspire | Boehringer Ingelheim International GmbH (Germany) | Inspire acquired rights to develop and market an intra- nasal form of epinastine in the U.S. and Canada for treating or preventing rhinitis | BI gets an up-front license fee and would get single-digit royalties on resulting sales; it also retained rights outside the U.S. and Canada; Inspire will fund development (2/21) |
KAI | Sankyo Co. Ltd. (subsidiary of Daiichi Sankyo Co. Ltd; Japan) | Collaboration to develop drugs for cardiovascular disease; the initial focus is on the Phase I/II delta protein kinase C inhibitor KAI-9803 | KAI gets $20M up front and could get mile- stones of up to $300M for two indications for KAI-9803, as well as milestone payments for future delta PKC inhibitors; Sankyo gets global rights, will fund all development and would pay double-digit royalties on sales (1/9) |
Kalypsys Inc.* | Alcon Inc. | Kalypsys will use its technologies for the discovery of ophthalmic drug candidates under a four-year deal | Kalypsys gets an access fee, research support and potential milestone payments, as well as royalties on any sales; Alcon also got preferred partnering access to compounds from Kalypsys programs (1/4) |
Keryx Bio- | Panion & BF Biotech Inc. (Taiwan) | Keryx gained rights outside Asia to Zerenex, an oral iron-based compound | Panion is entitled to up-front, milestone and royalty payments on the drug, which is in Phase II clinical development for treating hyperphosphatemia (2/15) |
LibraGen* | Pierre Fabre Medicament (France) | LibraGen will optimize the synthesis of a Pierre Fabre molecule | LibraGen will use its enzymatic technologies in the deal, terms of which were not disclosed (1/5) |
Locus | Eli Lilly and Co. | Locus will use its computational technologies to design small- olecule compounds for Lilly | The focus is a protein kinase target identified by Lilly; terms of the deal were not disclosed (1/31) |
Medarex | Organon NV (the Netherlands) | Organon got rights to use Medarex's UltiMAb technology for antibody discovery and development | Medarex is entitled to license fees, milestone payments and royalties on any resulting sales (2/1) |
MerLion | Novartis Institute for Tropical Diseases (Singapore) | Collaboration initially focused on discovering compounds for treating Dengue fever | MerLion will screen its natural compounds against an NITD target; Novartis has an option to license resulting candidates, and also can license compounds for different indications (1/19) |
Micromet AG* | Undisclosed pharmaceutical company | The unnamed company got rights to develop and sell a single-chain antibody product for treating cancer | The deal was made under Micromet's marketing deal with Enzon Pharmaceuticals Inc., which will get a share of any proceeds (1/18) |
Micromet AG* | Abbott Laboratories | Abbott gained a research license to single-chain antibody technology | The deal was made under Micromet's marketing deal with Enzon Pharmaceuticals Inc., which will get a share of any proceeds (1/18) |
Monogram | Merck & Co. Inc. | Monogram will apply its testing technologies for use in Phase III trials of MK-0518, Merck's HIV-1 integrase inhibitor | The PhenoSense and GeneSeq technologies will be used for HIV phenotypic and genotypic testing; terms of the deal were not disclosed (2/21) |
Nastech | Procter & Gamble Pharmaceuticals Inc. | P&G got worldwide rights to Nastech's PTH1-34, a para- thyroid hormone nasal spray for treating osteoporosis | Nastech gets $10M up front and milestone payments up to $22M in the first year; total payments could reach $577M if all goals are reached; Nastech also would get double-digit royalties on sales (2/1) |
Novosom | Boehringer Ingelheim Pharma GmbH (Germany) | Collaboration to validate liver and pulmonary targets in vivo using siRNA technology from Novosom | BI will fund the program; further terms were not disclosed (1/16) |
NPS | AstraZeneca plc (UK) | They extended for at least three years a deal to discover and develop drugs targeting metabotropic glutamate receptors | AstraZeneca already is in Phase I trials with a collaboration candidate; the focus is on treating central nervous system and gastrointestinal disorders; terms were not disclosed (2/8) |
Nuvelo Inc. | Bayer HealthCare AG (Germany) | Bayer got rights outside the U.S. to Nuvelo's Phase III thrombolytic drug alfimeprase; Nuvelo retained all U.S. rights | Nuvelo gets $50M up front, up to $165M in development milestones and up to $170M in sales milestones, as well as royalties up to 37.5%; Bayer also will pay 40% of development costs (1/5) |
Ocera | Kureha Corp. (Japan) | Ocera got rights to AST-120 in Europe and North America | Ocera is planning to start trials of the product, which is targeted at liver and gastro- intestinal diseases; the initial indication is Crohn's disease (1/17) |
Opsona | Wyeth Pharmaceuticals | Deal to discover and market compounds to treat inflammatory diseases, based on Toll-like receptor targets | Opsona gets an up-front payment and R&D funding, as well as potential milestone and royalty payments; it also has an option to develop resulting drugs in topical indications (2/13) |
Oscient | Pfizer SA de CV (Mexico) | Pfizer got rights to the antibiotic product Factive in Mexico | Oscient gets an up-front payment, as well as potential regulatory and sales milestones and royalties on sales (2/7) |
PerlegenSciences Inc.* | Pfizer Inc. | Four-year deal for whole- genome and replication studies to identify genes associated with diseases and to predict patient responses to certain drugs | Perlegen gets research payments; the companies will share in certain resulting intellectual property rights; the deal followed by one day a $50M equity investment in Perlegen by Pfizer; they have been partners since 2002 (12/28) |
Primagen | BioMerieux SA (France) | BioMerieux got rights to a newly discovered coronavirus implicated in respiratory diseases | BioMerieux plans to develop a test for the virus, CoV-NL63; it also has sublicensing rights; terms were not disclosed (2/1) |
Progenics | Wyeth | Deal to develop and market Progenics' Phase III product methylnaltrexone (MNTX) for treating opioid-induced side effects | Progenics gets $60M up front and up to $356.5M in milestone payments, as well as royalties on any sales; Progenics also retained a U.S. co-promotion option(12/23) |
PDL BioPharma | Merck & Co. Inc. | Merck got nonexclusive rights under PDL's humanization patents to develop antibodies against two antigens | PDL is entitled to an up-front licensing payment, development milestones and royalties on any sales; the antigens were not disclosed (12/3) |
Replidyne Inc.* | Forest Laboratories Inc. | Deal for the commercialization of Replidyne's oral antibiotic faropenem medoxomil in the U.S.; an NDA was filed in January | Replidyne gets $50M up front and potential milestone payments; it also would get royalties on sales; Replidyne retained certain marketing rights (2/13) |
Sangamo | Pfizer Inc. | New deal expands the scope of existing collaboration in the field of enhanced protein production | Pfizer will fund further research at Sangamo, which will use its zinc finger DNA-binding protein technology to develop additional cell lines (1/4) |
Sareum | UCB Pharma (Belgium) | Sareum will provide protein structure determination capabilities to accelerate UCB research in cancer | Sareum is entitled to access fees and milestone payments in the deal; further terms were not disclosed (1/26) |
Sareum | H. Lundbeck A/S (Denmark) | Sareum will provide protein structure determination capabilities to accelerate discovery research at Lundbeck | Sareum is entitled to research fees and milestone payments in the deal; specific terms were not disclosed (1/19) |
Sareum | Organon NV (the Netherlands) | Sareum will generate lead chemical series against two Organon autoimmune disease protein targets | Sareum is entitled to research fees and milestone payments in the deal; specific terms were not disclosed (1/17) |
Scottish | Chong Kun Dang (South Korea) | Collaboration on development of a drug for diabetes | Scottish Biomedical will provide chemistry and biology services on small molecules believed to be active against a diabetes target; terms were not disclosed (1/31) |
Senexis Ltd.* | BTG plc (UK) | Senexis got rights to inhibitors of amyloid-induced toxicity and neuroinflammation | BTG is entitled to milestone and royalty payments in the deal (2/2) |
Shanghai | Organon NV | Collaboration to advance Organon's program for identifying more-selective steroid hormone receptor modulators | The deal, initially for two years, will focus on the areas of rheumatoid arthritis, atherosclerosis and oncology; terms were not disclosed (1/24) |
Targacept | AstraZeneca plc (UK) | Deal to develop and market Targacept's Phase II drug TC- 734 for Alzheimer's disease and other cognitive disorders | Targacept gets $10M up front, $26M in research funding and would get $20M if AstraZeneca starts a Phase II program; Targacept also could earn about $244M in milestone payments and double-digit royalties on sales (12/28) |
Tripos Inc. | Wyeth Pharmaceuticals | Wyeth will use Tripos' discovery informatics technology as the basis for its information technology solution | Tripos expects to receive about $5M in software license and service fees over 12 to 18 months, with certain payments contingent on milestone achievements (1/11) |
Trubion | Wyeth Pharmaceuticals | Deal to develop and sell drugs for inflammatory diseases and cancer based on Trubion's Small Modular Immuno-pharmaceutical technology | Trubion gets $40M up front and up to $760M in milestone payments, as well as royalties on sales; Trubion retains an option to co-promote CD20- targeted therapies in the U.S. for certain indications; Wyeth also would invest in Trubion if it conducts an initial public offering (1/3) |
Vaccinex Inc.* | Schering AG (Germany) | Deal to identify disease targets and potentially develop drugs for treating certain cancers | Vaccinex gets a technology access fee and research funding and is eligible for milestone and royalty payments; its also has certain co-development options (2/10) |
VaxGen Inc. | Becton, Dickinson and Co. | Deal to evaluate BD's Micro Injection technology to deliver VaxGen's recombinant anthrax vaccine candidate | The collaboration will include a Phase I trial of the dermal injection; the work is being funded through a contract between BD and the Department of Defense (2/21) |
Xencor Inc.* | Centocor Inc. (unit of Johnson & Johnson) | Centocor got nonexclusive rights to use ImmunoFilter technology to evaluate the immunogenicity of its proteins | Xencor gets annual license fees under the multiyear deal; further terms were not disclosed (2/14) |
Xencor Inc.* | Eli Lilly and Co. | Lilly got nonexclusive rights to use Xencor's ImmunoFilter technology to evaluate the immunogenicity of its proteins | Terms of the multiyear licensing deal were not disclosed (1/18) |
Xencor Inc.* | F. Hoffmann-La Roche Ltd. (Switzerland) | They extended deal to create monoclonal antibodies with differentiated pharmacological profiles | Roche is applying Xencor's XmAb Fc domains to enhance the efficacy of an antibody against a cancer target; Xencor gets additional fees under the extension and remains entitled to milestone and royalty payments (1/4) |
YM BioSciences | Sanofi-Aventis Group (France) | Deal to investigate the combination of tesmilifene and docetaxel for treating metastatic breast cancer | The initial trial will enroll up to 39 patients; prior Phase III data on the combination showed increased survival; terms were not disclosed (1/10) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange. | |||